Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
Acetate → Bupropion
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | Acetate | HCID 175 | — |
| 반응물 | Phosphate | HCID 1061 | — |
| 반응물 | Bupropion Hydrochloride | HCID 62884 | — |
| 반응물 | Bupropion Hydrobromide | HCID 11984562 | — |
| 생성물 | Bupropion | HCID 444 | — |
반응 단계
The dissolution of bupropion HBr formulations according to the invention were assessed in three USP-3 media, i.e., SGF pH 1.2, Acetate Buffer pH 4.5 and Phosphate Buffer pH 6.8 over a period of 16 hours. These results are contained in FIG. 66. Particularly Bupropion HBr XL 348 mg tablets (final), Lot # Bup-HBr-XL-012-5; Wellbutrin XL 300 mg tablets (final), Lot # 05A116; Bupropion HBr XL 348 mg tablets ECl Lot # Bup-HBr-XL-012-5 (EC 32 mg wg) and Wellbutrin XL 300 mg tablets (EC10-Lot # 05D047 were assessed in SGF media pH 1.2 for 2 hours, Acetate Buffer pH 4.5 for 2 hours, and Phosphate Buffer SIF pH 6.8 for a total of 10 hours. The results are contained in the FIG. 66-68.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US07563823B2 |
| 출처 데이터셋 | uspto-grants-2009_07 |
| ORD ID | ord-40e1bbce3083436c940deac123c8d01f |
| 출처 메모 | uspto-grants-2009_07 |